SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
______________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15 (d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 22, 2003
United Therapeutics Corporation
_______________________________________
(Exact Name of Registrant as Specified in Charter)
| Delaware | 000-26301 | 52-1984749 | ||
|
|
||||
| (State or Other | (Commission | (I.R.S. Employer | ||
| Jurisdiction of | File Number) | Identification Number) | ||
| Incorporation) |
| 1110 Spring Street | ||
| Silver Spring, MD | 20910 | |
|
|
||
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code:
(301) 608-9292
———————————————
Item 5. Other Events.
On September 22, 2003, United Therapeutics Corporation (the “Company”) issued a press release announcing that the French Regulatory Agency has recommended that Remodulin not be approved in France based on insufficient demonstration of clinical efficacy for the claimed indication. A copy of the press release is attached hereto and incorporated herein by this reference.
Item 7. Exhibits
(c) Exhibits
| Exhibit No. | Description of Exhibit | |
| 99.1 | Press release dated September 22, 2003 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| UNITED THERAPEUTICS CORPORATION | |||
| Dated: | September 23, 2003 | By: | /s/ Paul A. Mahon |
| Name: | Paul A. Mahon | ||
| Title: | General Counsel | ||
EXHIBIT INDEX
| Exhibit No. | Description of Exhibit | |
| 99.1 | Press Release dated September 22, 2003 |